Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma

NCT01436656 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01436656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01436656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 5, 2011
Completion date
November 7, 2022
Enrollment
107 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma and metastatic colorectal cancer